Search research articles
Contact Us
Filters
Showing results (11-20 of 126) with videos related to
Page
of 13
Sort By:
Nature Reviews. Clinical Oncology
|
February 15, 2012
Antiangiogenic therapy--evolving view based on clinical trial results
Gordon C Jayson, Daniel J Hicklin, Lee M Ellis
BMC Nephrology
|
October 24, 2019
Cancer patterns and association with mortality and renal outcomes in non-dialysis dependent chronic kidney disease: a matched cohort study
Rajkumar Chinnadurai, Emma Flanagan, Gordon C Jayson, et al.
The Journal of Biological Chemistry
|
February 25, 2014
Ovarian cancer cell heparan sulfate 6-O-sulfotransferases regulate an angiogenic program induced by heparin-binding epidermal growth factor (EGF)-like growth factor/EGF receptor signaling
Claire L Cole, Graham Rushton, Gordon C Jayson, et al.
The Lancet. Oncology
|
May 4, 2010
The ethical and scientific case for phase 2C clinical trials
Ying-Kiat Zee, Sarah W Chan, John Harris, et al.
Current Opinion in Oncology
|
September 1, 2007
Antiangiogenic therapy for ovarian cancer
Daniela D Rosa, Andrew R Clamp, Fiona Collinson, et al.
Lancet (London, England)
|
February 9, 2016
Antiangiogenic therapy in oncology: current status and future directions
Gordon C Jayson, Robert Kerbel, Lee M Ellis, et al.
Organic Letters
|
December 18, 2012
First gram-scale synthesis of a heparin-related dodecasaccharide
Steen U Hansen, Gavin J Miller, Gordon C Jayson, et al.
British Journal of Cancer
|
October 30, 2021
The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer
Alexander D Murphy, Robert D Morgan, Andrew R Clamp, et al.
Lancet (London, England)
|
April 29, 2014
Ovarian cancer
Gordon C Jayson, Elise C Kohn, Henry C Kitchener, et al.
The Journal of Organic Chemistry
|
March 22, 2016
An Updated Synthesis of the Diazo-Transfer Reagent Imidazole-1-sulfonyl Azide Hydrogen Sulfate
Garrett T Potter, Gordon C Jayson, Gavin J Miller, et al.
Page
of 13
Search research articles
Search
Showing results (11-20 of 126) with videos related to
Sort By:
Page
of 13
Nature Reviews. Clinical Oncology
|
February 15, 2012
Antiangiogenic therapy--evolving view based on clinical trial results
Gordon C Jayson, Daniel J Hicklin, Lee M Ellis
BMC Nephrology
|
October 24, 2019
Cancer patterns and association with mortality and renal outcomes in non-dialysis dependent chronic kidney disease: a matched cohort study
Rajkumar Chinnadurai, Emma Flanagan, Gordon C Jayson, et al.
The Journal of Biological Chemistry
|
February 25, 2014
Ovarian cancer cell heparan sulfate 6-O-sulfotransferases regulate an angiogenic program induced by heparin-binding epidermal growth factor (EGF)-like growth factor/EGF receptor signaling
Claire L Cole, Graham Rushton, Gordon C Jayson, et al.
The Lancet. Oncology
|
May 4, 2010
The ethical and scientific case for phase 2C clinical trials
Ying-Kiat Zee, Sarah W Chan, John Harris, et al.
Current Opinion in Oncology
|
September 1, 2007
Antiangiogenic therapy for ovarian cancer
Daniela D Rosa, Andrew R Clamp, Fiona Collinson, et al.
Lancet (London, England)
|
February 9, 2016
Antiangiogenic therapy in oncology: current status and future directions
Gordon C Jayson, Robert Kerbel, Lee M Ellis, et al.
Organic Letters
|
December 18, 2012
First gram-scale synthesis of a heparin-related dodecasaccharide
Steen U Hansen, Gavin J Miller, Gordon C Jayson, et al.
British Journal of Cancer
|
October 30, 2021
The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer
Alexander D Murphy, Robert D Morgan, Andrew R Clamp, et al.
Lancet (London, England)
|
April 29, 2014
Ovarian cancer
Gordon C Jayson, Elise C Kohn, Henry C Kitchener, et al.
The Journal of Organic Chemistry
|
March 22, 2016
An Updated Synthesis of the Diazo-Transfer Reagent Imidazole-1-sulfonyl Azide Hydrogen Sulfate
Garrett T Potter, Gordon C Jayson, Gavin J Miller, et al.
Page
of 13